Armodafinil for ADHD
Armodafinil is a stimulant.
It is clearly different from amphetamines.
Amordafinil is the (R)-enantiomer of the racemate modafinil.
Other names:1
- C15H15NO2S
- (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
- (-)-(R)-modafinil
- (-)-modafinil
- (R)-(-)-modafinil
- (R)-modafinil
- Armodafinil
- Armodafinilo
- Armodafinilum
- R-modafinil
- CEP 10953
- CEP-10952
- CEP-10953
- CRL 40982
- CRL-40982
Armodafinil has been approved in the USA since 2007 for the treatment of
- excessive daytime sleepiness in adults with obstructive sleep apnea
- Narcolepsy
- Shift worker syndrome
US patent protection ends in 2023.
Brand name: Nuvigil®
- 1. Mechanisms of action of armodafinil
- 2. Degradation of armodafinil
- 3. Interactions
- 4. Side effects, contraindication
- 5. Armodafinil for ADHD
1. Mechanisms of action of armodafinil
The exact mechanism of action is unknown1
Armodafinil belongs to the stimulant class of eugeroics. These cause a long-lasting mental arousal.
It activates the sympathetic nervous system.
Armodafinil does not bind to or inhibit any receptors or enzymes that control sleep-wake regulation.
Armodafinil works neither directly nor indirectly
- as a dopamine receptor agonist
- as an α1-adrenoceptor agonist
Armodafinil (like modafinil) binds to the DAT and acts as a dopamine reuptake inhibitor (stronger than modafinil).23
Tmax:
- if taken without food after 2 hours
- when taken with food after 4 to 6 hours
2. Degradation of armodafinil
Half-life: 15 hours
Armodafinil is broken down by
- CYP3A4/5 (second most important degradation pathway)
- hydrolytic deamidation (most important degradation pathway)
- S-oxidation
- Hydroxylation of the aromatic ring with subsequent glucuronide conjugation of the hydroxylated products
Metabolites:
- R-Modafinilic acid
- Modafinil sulfone
3. Interactions
- Grapefruit juice
- St. John’s wort
- oral contraceptives
- Anticonvulsants
- Anticoagulants (anticoagulants)
- Ciclosporin (an immunosuppressant)
Inductor from
- CYP3A4 (weak)
- CYP3A5 (strength unknown)
- CYP1A2 (strength unknown)
- CYP2B6 (strength unknown)
Inihbitor from
- CYP2C19 (moderate)
- CYP2C9 (strength unknown)
4. Side effects, contraindication
4.1. Side effects
- Headache
- Nausea
- Dizziness
- Sleep disorders
- mild allergic reactions
- Skin rashes
- Hay fever
Severe allergic skin reactions are possible.
4.2. Contraindication
The dose should be reduced in the case of severe hepatic or renal insufficiency
5. Armodafinil for ADHD
Armodafinil could be helpful in the treatment of ADHD in adults.
A meta-analysis of 86 studies4 found that in adults with sleep disorders and other illnesses, acute and chronic administration improved
- Alertness
- Memory
- Impulse control
- Executive functions
In addition, there were indications of an improvement in
- cognitive functions
- Mood swings
Another meta-study found 4 studies with n = subjects that investigated armodafinil in ADHD.5
Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G, Newman AH (2012): R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012 Sep 1;72(5):405-13. doi: 10.1016/j.biopsych.2012.03.022. PMID: 22537794; PMCID: PMC3413742. ↥
Keighron JD, Quarterman JC, Cao J, DeMarco EM, Coggiano MA, Gleaves A, Slack RD, Zanettini C, Newman AH, Tanda G (2019): Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell. ACS Chem Neurosci. 2019 Apr 17;10(4):2012-2021. doi: 10.1021/acschemneuro.8b00340. PMID: 30645944; PMCID: PMC8294083. ↥
Lamas-Aguilar R, Diaz-Ruiz A, Navarro L, Miranda-Ojeda R, Martínez-Cárdenas MLÁ, Mata-Bermudez A, Rios C (2024): Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review. Curr Neuropharmacol. 2024 Mar 14. doi: 10.2174/1570159X22666240131121642. PMID: 38486390. METASTUDY ↥
Miskowiak KW, Obel ZK, Gugliemo R, Bonnin CDM, Bowie CR, Balanzá-Martínez V, Burdick KE, Carvalho AF, Dols A, Douglas K, Gallagher P, Kessing LV, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes PRA, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Hasler G (2024): Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. Bipolar Disord. 2024 Mar 3. doi: 10.1111/bdi.13414. PMID: 38433530. REVIEW ↥